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In this issue of Cell Stem Cell, Cui et al. (2009) provide snapshots of histone modification maps for two
different stages of human blood cell development. Revealing chromatin-state maps in model cell types will
provide an important framework in which to consider epigenetic controls at molecular and systematic levels.Virtually all development is epigenetic, i.e.,
the underlying DNA sequence remains
static. Each step, from totipotency to
terminal differentiation, requiresestablish-
ment of a stable epigenetic state engaging
specific developmental commitments that
are faithfully transmitted to daughter cells.
As illustrated by Conrad H. Waddington in
the 1940s, differentiation is similar to a ball
rollingdownalongbranchingvalleys: once
it has entered its final valley, it cannot
easily cross the ridge into the neighboring
one or return to its position uphill. It is
believed that epigenetic mechanisms
involving DNA methylation and histone
modifications progressively restrict
lineage potential. Knowledge of the epige-
netic landscape for diverse cell types will
illuminate epigenetic controls that underlie
normal development. Cui et al. provide
a step in this direction (Cui et al., 2009).
The realization that epigenetic or cell
fates are not as fixed as originally con-
ceived by Waddington provides a founda-
tion for reprogramming. For example,
merely a few transcription factors repro-
gram fibroblasts and terminally differenti-
ated B cells or skin cells into induced
pluripotent stem cells (Maherali and Ho-
chedlinger, 2008). Cells of one hematopoi-
etic lineage can be converted to another
through forced expression of single factors
(Orkin and Zon, 2008). In addition, cancer
cells, which often appear to acquire
characteristics of embryonic cells, harbor
epigenetic defects in genes implicated in
DNA methylation, histone modifications,
and chromatin remodeling. Nevertheless,
reprogramming, dedifferentiation, and
transdifferentiation are inefficient pro-
cesses that need to overcome epigenetic
barriers. Generation and comparison
of chromatin landscapes of cells under
normal and experimentally, or genetically
varied, conditions should provide insights
into plasticity and reprogramming andperhaps suggest means to improve
reprogramming efficiency.
Chromatin-associated histones are
subject to more than 100 posttranslational
modifications, including methylation, acet-
ylation,phosphorylation,ADP-ribosylation,
and ubiquitination. According to the
‘‘histone code’’ hypothesis, combinations
of these modifications specify chromatin
structure and gene activity and predict
cellular states (Jenuwein and Allis, 2001).
The techniques of ChIP-chip and ChIP-
seq, in which chromatin is immunoprecipi-
tated with antibody against a modified
histone or a chromatin-associated protein
and then hybridized to an array or sub-
jected to DNA sequencing, are being
used intensively in genome-wide mapping
analysis of histone and chromatin marks.
Studies in human andmouse ESCs, neural
progenitor cells, fibroblasts, hepatocytes,
and T cells have revealed patterns of
histone methylation at promoters,
enhancers, insulators, and transcribed
regions (Barski et al., 2007; Guenther
et al., 2007; Mikkelsen et al., 2007; Mohn
et al., 2008; Pan et al., 2007; Zhao et al.,
2007). Whereas histone acetylation tightly
correlates with open chromatin and gene
activation, methylation is associated with
different effects depending on the position
and state (Figure 1). Trimethylation on
histone H3 lysine 4 (H3K4) and lysine 36
(H3K36), and monomethylation on H3K4,
H3K9, H3K27, H4K20, and H2BK5, corre-
lates with gene activation. Di- and/or
trimethylationonH3K9andH3K27 is linked
to repression. While multiple modifications
with similar functions may reinforce the
robustness of a chromatin state, the biva-
lency of apparently opposite H3K4me3
and H3K27me3 marks has been hypothe-
sized to create a poised chromatin state
for rapid induction upon differentiation
cues. Impressively large numbers of biva-
lent domains have been identified in notCell Stem Conlypluripotent andmultipotent stemcells,
but also in cells with limited lineage choice,
including resting CD4+ T cells, fibroblasts,
and neurons, suggesting unexpectedplas-
ticity in the epigeneticmemoryof differenti-
ated cells.
In this issue, Cui et al. report the genera-
tion of high-resolution genome-wide maps
of eight histone modifications, as well as
histone variant H2A.Z and RNA poly-
merase II (Pol II), together with gene
expression profiles in human CD133+
hematopoietic stem cells/progenitor
(HSCs/progenitor) cells and CD36+ eryth-
rocyte precursor (or erythroblast) cells
(Cui et al., 2009). The information provided
by Cui et al. is vast and demands attention
from readers. Their major findings are as
follows: (1) Global chromatin modification
patterns are similar and correlate with
gene expression in two cell states. For
example, a positive correlation exists
between gene expression and H3K4me3,
H3K4me1, H3K9me1, H3K36me3, and
H4K20me1 in both promoter regions and
gene bodies. At promoters, H2A.Z pres-
ence positively correlates with expression,
whereas in gene bodies, H2A.Z and
H3K27me1 correlate positively with less-
active genes but negatively with more-
active genes. H3K27me3 and H3K9me3
show inverse correlationwith gene expres-
sion. Thus, combinatorial modification
patterns at promoters and gene bodies
support cooperative regulation of tran-
scription through histone modifications.
(2) Epigenetic changes in regulatory loci
correlate with expression changes during
erythroid differentiation, supporting the
notion that epigenetics accompanies
lineage restriction. Differentiated erythro-
blasts achieve genome-wide silencing of
genes involved in other blood lineages by
switching off the active H3K4me3 mark
in 53% of bivalent genes detected in
HSCs/progenitor cells (Figure 1). (3) Inell 4, January 9, 2009 ª2009 Elsevier Inc. 1
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lent H3K27me3 in erythroblasts, 19% of
bivalent genes that retain monovalent
H3K4me3 are more likely associated with
H2A.Z, RNA Pol II, and monomethylation
on H3K4, H3K9, and H4K20 in HSCs/
progenitor cells. These modifications may
thus contribute to the fate of bivalent genes
in stem cells, and the chromatin structure
may be already programmed at the HSC/
progenitor stage for what takes place later
during differentiation. (4) Erythrocyte-
specific genes including CD36, b-globin,
and KLF1 are associated with H3K4me1,
H3K9me1, and H3K27me1 in their
enhancers or locus control regions in
HSCs/progenitor cells. This observation
implies a role of monomethylation marks
Figure 1. Combinatorial Epigenetic
Modifications Correlate with Gene Status
Active genes frequently associate with H2A.Z, RNA
Pol II, andmultiplehistonemodifications (lower left).
Repressed genes are often marked by H3K27me2,
H3K27me3, H3K9me2, and H3K9me3 (lower
right). Poised genes (center) marked by bivalent
H3K4me3 andH3K27me3 inHSCs/progenitor cells
resolve into three fates during erythroid differentia-
tion: gene activation (upper left), maintenance of bi-
valency, and gene repression (upper right). Bivalent
genes that becomeactivated in erythroblasts (19%)
are more likely associated with H2A.Z, Pol II,
H3K4me1, H3K9me1, and H4K20me1 in HSCs/
progenitor cells. Thus, the fate of bivalent genes
may be programmed in a manner dependent on
additional modification marks present in HSCs/
progenitor cells. Lastly, correlated H3K4me1,
H3K27me1, and H3K9me1 may represent another
mechanism to prime gene activation in HSCs/
progenitor cells.2 Cell Stem Cell 4, January 9, 2009 ª2009 Ein maintaining the activation potential
required for lineage specification and
suggests a means to uncover functional
enhancers. In addition, bivalent marks are
not present at the CD36, b-globin, and
erythrocyte transcription factor Gata1 and
KLF1 genes in HSCs/progenitor cells.
Thus, monomethylation on H3K4, H3K9,
andH3K27may represent anothermecha-
nism inaddition tobivalentmodifications to
prime gene activation. However, it is
unclear whether these enhancer elements
may gain bivalency during transitions to
common myeloid progenitors (CMPs) or
myeloid/erythroid precursors (MEPs)
before maturation into erythrocytes.
ThestudyofCui etal. (2009)supports the
combinatorial effects of histone modifica-
tions on gene activity and reveals general
features of this correlation during stem
cell differentiation. However, general rules
do not apply in all situations. For example,
actively expressed CD36 bears the
‘‘repressive’’ H3K9me3 at the promoter.
While a majority of bivalent genes in
HSCs/progenitor cells that retain monova-
lent H3K4me3 are activated in erythro-
blasts, nearly 10% (53 genes) of them
exhibit decreased expression. Thus, it is
worth asking whether an epigenetic index-
ing system exists for our genome. If so, the
histone code is vastly more complicated
than the genetic code. In considering the
Cui et al. data, it is important to remember
that human CD133+ HSCs/progenitor cells
are composed of quiescent long-term
HSCs, cycling short-term HSCs and
progenitors with different transcription
programs and differentiation potentials.
The data collected from thismixed popula-
tionmay overestimate complexity of single
populations. Nonetheless, hematopoiesis
is an exceptional paradigm in which to
explore how the epigenomics controls
stem cell differentiation and organogen-
esis. The findings in human should be
confirmed in mouse, because better-
defined cell surface markers in mouse
hematopoiesis enable the isolation of
purer, functionally validated populations
for epigenetic profiling.
As methods for genome-wide identifi-
cation of histone marks become more
routine and less expensive, we should
witness the generation of chromatin-state
maps for multiple modifications in a vast
array of cell types and how these maps
change with environmental signals. These
mapsmust be integrated and evaluated inlsevier Inc.the context of existing data and genome
annotations. It will be particularly impor-
tant to integrate genome-wide transcrip-
tion factor binding with chromatin-state
maps in order to determine how transcrip-
tion networks interact with epigenetic
marking systems to achieve cellular
stability. As nucleosome juxtaposition
may bring distal regulatory elements
together to regulate transcription, the epi-
genomic landscape should be viewed in
three-dimensional space. Most published
epigenomic studies thus far focus on
regionssurroundingorwithingenes.Since
>95% of human genome is non-protein-
coding DNA necessary for genome
stability, chromatin structure, and gene
activity, the epigenetic landscape in inter-
genic, intron, repetitive regionswill need to
be characterized as well in order to deci-
pher theepigenomics in its entirety. Lastly,
epigenetic data should be displayed in
a readily accessible fashion for nonepige-
netic investigators. Further interrogation
of the general nature of the epigentic
code will reward us with a better under-
standing of the role of epigenomics in
development and disease pathology, and
also with new therapeutic tools through
manipulating the epigenetic state of cells.
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